OTCMKTS:NVTRQ

Nuvectra (NVTRQ) Stock Forecast, Price & News

$0.02

-0.01 (-25.00%)

(As of 06/2/2020)

Compare

Today's Range: $0.02
▼
$0.02
50-Day Range: $0.0150
▼
$0.0150
52-Week Range: $0.01
▼
$4.30

Volume: 382,600 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Nuvectra (OTCMKTS:NVTRQ) Stock

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.

Receive NVTRQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvectra and its competitors with MarketBeat's FREE daily newsletter.

NVTRQ Stock News Headlines

May 4, 2023 | americanbankingnews.com

Nuvectra (OTCMKTS:NVTRQ) Stock Passes Below 50 Day Moving Average of $0.02

April 9, 2023 | americanbankingnews.com

Nuvectra (OTCMKTS:NVTRQ) Stock Price Crosses Below Fifty Day Moving Average of $0.02

June 9, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.

April 1, 2023 | americanbankingnews.com

Nuvectra (OTCMKTS:NVTRQ) vs. Motus GI (NASDAQ:MOTS) Financial Comparison

March 4, 2022 | benzinga.com

Global Nerve Repair & Regeneration Market (2021 to 2026) - by Product, Application and Geography - Benzin - Benzinga

March 2, 2022 | businesswire.com

Outlook on the Nerve Repair & Regeneration Global Market to 2026 - Featuring Medtronic, Abbott Laboratories and LivaNova Among Others - ResearchAndMarkets.com - Business Wire

February 17, 2022 | globenewswire.com

Integer Holdings Corporation Reports Results for Fourth Quarter and Full Year 2021 - GlobeNewswire

February 17, 2022 | stockhouse.com

Integer Holdings Corporation Reports Results for Fourth Quarter and Full Year 2021 - Stockhouse

June 9, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

February 15, 2022 | benzinga.com

Global Bioelectric Medicine Market (2020 to 2030) - by Product Type, End-user and Region - Benzinga - Benzinga

February 8, 2022 | globenewswire.com

Global Spinal Cord Stimulation Market (2021 to 2026) - by Product, Disease, End-user and Geography - GlobeNewswire

December 20, 2021 | benzinga.com

Global Spinal Cord Stimulation Market Research Report 2021 - Benzinga - Benzinga

December 15, 2021 | streetinsider.com

Form DEF 14A MERIDIAN BIOSCIENCE INC For: Jan 26 - StreetInsider.com

October 28, 2021 | globenewswire.com

Integer Holdings Corporation Reports Third Quarter 2021 Results - GlobeNewswire

September 17, 2021 | bizjournals.com

After 3 years without a CEO, Redmond startup Kymeta formalizes leadership structure - Puget Sound Business Journal (Seattle)

July 29, 2021 | globenewswire.com

Integer Holdings Corporation Reports Second Quarter 2021 Results - GlobeNewswire

July 7, 2021 | finance.yahoo.com

Spinal Cord Stimulation Market Research Report by Product, by Application, by End User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19 - Yahoo Finance

July 1, 2021 | finance.yahoo.com

Neuromodulation Devices (Neurology Devices) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) - Yahoo Finance

April 22, 2021 | globenewswire.com

Brain Implant Market Value Predicted To Reach US$ 7,895.4 Million By 2027 Covering Pre and Post COVID-19 Market Analysis: Acumen Research And Consulting - GlobeNewswire

April 21, 2021 | stockhouse.com

Brain Implant Market Value Predicted To Reach US$ 7895.4 Million By 2027 Covering Pre and Post COVID-19 Market Analysis: Acumen Research And Consulting - Stockhouse

April 14, 2021 | ca.finance.yahoo.com

Serena Williams signs programming deal with Amazon Studios - Yahoo Canada Finance

April 14, 2021 | au.finance.yahoo.com

Nintendo’s Switch Lite will soon come in deep blue - Yahoo Finance Australia

April 14, 2021 | benzinga.com

ProbioLite Reviews - Does Golden After 50's Probio-Lite Supplement Work or Scam? Safe Ingredients? By Nuvectramedical - Benzinga

March 27, 2021 | globenewswire.com

Vista Clear Reviews - Is VistaClear Vision Formula Worth Buying? Safe Ingredients? User Reviews by Nuvectramedical - GlobeNewswire

March 26, 2021 | globenewswire.com

The Global Neurostimulation Devices Market is expected to grow by $ 2.23 bn during 2021-2025, progressing at a CAGR of 8% during the forecast period - GlobeNewswire

March 9, 2021 | finance.yahoo.com

Zenith Labs’ Hearing X3 Reviews - Is Hearing X3 an Effective Tinnitus Relief Supplement? Reviews by Nuvectramedical - Yahoo Finance

March 7, 2021 | globenewswire.com

BioFit Probiotic Reviews: Is BioFit the Best Probiotic Weight Loss Support? Ingredients & Side Effects - Nuvectramedical - GlobeNewswire

See More Headlines

NVTRQ Price History

30 days | 90 days | 365 days | Advanced Chart

NVTRQ Company Calendar

Last Earnings: 10/29/2018
Today: 6/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:NVTRQ
Previous Symbol: NASDAQ:NVTRV
CUSIP: N/A
CIK: 1648893
Web: www.nuvectramed.com
Phone: 214-474-3103
Fax: N/A
Employees: 197
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: N/A

Key Executives

Dr. Fred B. Parks Ph.D. (Age 72)
CEO & Director

Mr. Joseph Paul Hanchin (Age 57)
Pres

Mr. Walter Z. Berger (Age 63)
COO, CFO & Exec. VP

Ms. Jennifer J. Kosharek (Age 38)
VP, Controller & Principal Accounting Officer

Mr. Benjamin Tranchina
Chief Technology Officer

Key Competitors

View All Competitors

NVTRQ Stock - Frequently Asked Questions

How have NVTRQ shares performed in 2023?: Nuvectra's stock was trading at $0.0150 at the beginning of 2023. Since then, NVTRQ stock has increased by 0.0% and is now trading at $0.0150.
View the best growth stocks for 2023 here.
How were Nuvectra's earnings last quarter?: Nuvectra Corp (OTCMKTS:NVTRQ) announced its quarterly earnings results on Monday, October, 29th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by $0.01. The firm had revenue of $14.22 million for the quarter, compared to analysts' expectations of $12.38 million.
What is Nuvectra's stock symbol?: Nuvectra trades on the OTCMKTS under the ticker symbol "NVTRQ."

How do I buy shares of Nuvectra?: Shares of NVTRQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Nuvectra's stock price today?: One share of NVTRQ stock can currently be purchased for approximately $0.02.
How many employees does Nuvectra have?: The company employs 197 workers across the globe.
How can I contact Nuvectra?: Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The official website for the company is www.nuvectramed.com. The company can be reached via phone at 214-474-3103 or via email at investors@nuvectramed.com.

This page (OTCMKTS:NVTRQ) was last updated on 6/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial